IP Library Granted Patent US 9,970,001
Granted Patent B2
US 9,970,001 · App. 14/731,821 · Granted May 15, 2018

Methods and compositions for nuclease design

Inventor: Jeffrey C. Miller (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N15/01C12N9/22C12N15/102C12N15/63C07K2319/00C12Y301/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,970,001
App. No.
14/731,821
Granted
May 15, 2018
Kind
B2
Abstract

Methods and compositions for genetic alteration of cells are provided.

Claims (10)

1. A Cas polypeptide comprising a S. pyogenes Cas 9 (spCas9) protein, wherein the Cas polypeptide that forms a complex with a single guide RNA (sgRNA) that binds to a target sequence in an endogenous gene, the target sequence comprising a protospacer adjacent motif (PAM) sequence of 5′VGGC (i.e. 5′ AGGC, CGGC or GGGC) at the 3′ end of the target sequence, wherein the complex exhibits increased binding specificity to and cleavage of the target sequence by the Cas/sgRNA complex as compared to a target sequence comprising a PAM sequence of NGGD (i.e. 5′ NGGA, NGGG or NGGT).

2. The Cas polypeptide of claim 1 , wherein the spCas9 polypeptide is a mutant spCas9 protein and the mutations are in the α-helical lobe of the Cas9 protein.

3. The Cas polypeptide of claim 2 , wherein the mutations are in the region of the Cas9 protein extending between amino acid 78 to amino acid 718 of SEQ ID NO:2.

4. The Cas polypeptide of claim 2 , wherein the mutations are in the C-terminal domain of the Cas polypeptide.

5. The Cas polypeptide of claim 4 , wherein the mutations are between amino acids 1099 to 1368 or 1200 to 1368 of SEQ ID NO:2.

6. The Cas polypeptide of claim 2 , wherein the mutation is in an altered tryptophan containing loop between amino acids 447-502 or 1102-1137 of SEQ ID NO:2.

7. A complex comprising the Cas polypeptide associated with the sgRNA of claim 1 and the target sequence in the endogenous gene.

8. The complex of claim 7 , wherein the target sequence is in an endogenous safe harbor gene.

9. A method of cleaving a target sequence in a cell, the method comprising generating a complex of claim 7 into the cell such that the target is cleaved.

10. A cell comprising a cleaved target made by the method of claim 9 .

Assignments (2)
CHANGE OF NAME Recorded Jan 30, 2018
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 045194/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2015
From: MILLER, JEFFREY C.
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 035804/0412 →
Continuity (2)
Provisional Application 62008359 · Jun 5, 2014
Related Publication 20150353917A1 · Dec 10, 2015